VelosBio to be Acquired by Merck…

 
March 19, 2008

Finding the right business model for systems biology (SB) technology providers has been challenging — that’s hardly a new theme in biotech. Most SB pioneers were founded as platform providers but soon encountered difficulties growing their sales sufficiently to increase valuations. Genstruct, a pioneer in using computational approaches to infer mechanistic hypotheses from large experimental data sets, is no exception.